In this Issue:
Colorectal cancer screening
Re-examining PFS as a clinically meaningful endpoint
Aflibercept + FOLFIRI in second-line treatment of mCRC
Afatinib vs cetuximab in KRAS wild-type mCRC
Organ preservation for rectal cancer
Combination therapy with oxaliplatin beneficial in CRC
Noninvasive monitoring of anti-EGFR treatment?
RAS mutation predicts non-response to EGFR antibodies
Abituzumab may benefit KRAS wt mCRC
Rising incidence of early-onset CRC in Australia
Please login below to download this issue (PDF)